The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Pathway-Specific Dopamine Abnormalities in Schizophrenia
Open accessAbstract
In light of the clinical evidence implicating dopamine in schizophrenia, and the prominent hypotheses put forth regarding alterations in dopaminergic transmission in this disease, molecular imaging has been used to examine multiple aspects of the dopaminergic system. Here we review the imaging methods used and compare the findings across the different molecular targets. Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions, and even to other extrastriatal subcortical regions not previously considered to be “hypodopaminergic” in schizophrenia. These findings yield a new topography for the dopaminergic dysregulation in schizophrenia. In this review we discuss the dopaminergic innervation within the individual projection fields to provide a topographical map of this dual dysregulation and explore potential cellular and circuit based mechanisms for brain region-dependent alterations in dopaminergic parameters. This refined knowledge is essential to better guide translational studies and efforts in early drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The reward circuit: linking primate anatomy and human imaging
Haber, S. N., & Knutson, B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.129 · Cited by 3,718
Getting formal with dopamine and reward
Schultz, W. (2002) · Neuron · doi:10.1016/s0896-6273(02)00967-4 · Cited by 2,574
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Self-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 1×
“Using D2 radiotracers and a psychostimulant challenge, four studies showed higher release in the striatum of antipsychotic-free (Rx-free) patients compared to healthy controls (HC) (52-55).”
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 1×
“Furthermore, baseline synaptic DA assessed with a depletion paradigm (57) were enhanced in striatum in SZ and were correlated with amphetamine-induced release in a cohort of antipsychotic-naïve patients (58).”
Self-citationUnique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system
Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., & Roeper, J. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.022 · Cited by 976
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Self-citationImaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803
Self-citationGraybiel, A. M., & Ragsdale, C. W. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.11.5723 · Cited by 784
Monitoring and Care of Young People at Incipient Risk of Psychosis
Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.283 · Cited by 772
Dopaminergic modulation of synaptic transmission in cortex and striatum
Tritsch, N. X., & Sabatini, B. L. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.023 · Cited by 756
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724
Self-citationIncreased dopamine transmission in schizophrenia: relationship to illness phases
Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00067-0 · Cited by 715
Self-citationDecreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710
Pruessner, J. C., Champagne, F., Meaney, M. J., & Dagher, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3422-03.2004 · Cited by 709 · cited 1×
“Earlier detection and awareness of the prodromal phase of the disease (7,8) resulted in testing earlier stages of SZ (9–11), whereas stress paradigms (12,13) allowed probing responsiveness of the system to a relevant risk factor for the disease (14,15), together yielding a replicable set of findings across laboratorie…”
Prediction of psychosis. A step towards indicated prevention of schizophrenia.
Yung, A. R., Phillips, L., McGorry, P. D., McFarlane, C. A., Francey, S. M., Harrigan, S., Patton, G. C., & Jackson, H. J. (1998) · PubMed · Cited by 698
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652
Prediction of psychosis: A step towards indicated prevention of schizophrenia
Yung, A. R., Phillips, L. J., McGorry, P. D., McFarlane, C. A., Francey, S., Harrigan, S., Patton, G. C., & Jackson, H. J. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297602 · Cited by 630
Joel, D., & Weiner, I. (2000) · Neuroscience · doi:10.1016/s0306-4522(99)00575-8 · Cited by 614
Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates
Berger, B., Gaspar, P., & Verney, C. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90179-x · Cited by 588
Martinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D.-R., Huang, Y., Cooper, T., Kegeles, L., Zarahn, E., Abi-Dargham, A., et al. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000048520.34839.1a · Cited by 569
Self-citationIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Self-citationYung, K. K. L., Bolam, J. P., Smith, A. D., Hersch, S. M., Ciliax, B. J., & Levey, A. I. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00536-e · Cited by 542
Provocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 532
The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.
van Rossum, J. M. (1966) · PubMed · Cited by 510
Antipsychotic Drugs, Neurotransmitters, and Schizophrenia
CARLSSON, A. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.2.164 · Cited by 498
Hersch, S., Ciliax, B., Gutekunst, C., Rees, H., Heilman, C., Yung, K., Bolam, J., Ince, E., Yi, H., & Levey, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-07-05222.1995 · Cited by 483
Basal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments
Crittenden, J. R., & Graybiel, A. M. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00059 · Cited by 481
Sesack, Sr., Aoki, C., & Pickel, V. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-01-00088.1994 · Cited by 461 · cited 1×
“D2 ligand displacement by challenge-induced DA release occurs at the subset of D2 receptors that are in close proximity to DA release sites (28-32).”
Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J. L., Narendran, R., Gil, R., Hackett, E., Girgis, R., Ojeil, N., Moore, H., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2414 · Cited by 398
Self-citationCools, R., Frank, M. J., Gibbs, S. E., Miyakawa, A., Jagust, W., & D'Esposito, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4467-08.2009 · Cited by 364
Dopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [ 18 F]-DOPA PET Imaging Study
Howes, O. D., Bose, S. K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L. R., Murray, R. M., & McGuire, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010160 · Cited by 343
Elevated dopa decarboxylase activity in living brain of patients with psychosis
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342 · cited 1×
“Higher striatal [(18)F]DOPA was first reported in psychosis related to epilepsy and SZ (40).”
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 325
Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients
Hietala, J., Syvälahti, E., Kuoppamäki, M., Hietala, J., Syvälahti, E., Haaparanta, M., Kuoppamäki, M., Ruotsalainen, U., Vuorio, K., Räkköläinen, V., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91801-9 · Cited by 321
Working Memory Capacity Predicts Dopamine Synthesis Capacity in the Human Striatum
Cools, R., Gibbs, S. E., Miyakawa, A., Jagust, W., & D'Esposito, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4475-07.2008 · Cited by 302
Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., Valmaggia, L., Allen, P., Murray, R., & McGuire, P. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.20 · Cited by 292
Lindström, L. H., Gefvert, O., Hagberg, G., Lundberg, T., Bergström, M., Hartvig, P., & Långström, B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00109-2 · Cited by 284
Dopamine release in the basal ganglia
Rice, M. E., Patel, J. C., & Cragg, S. J. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.066 · Cited by 282
Increased stress-induced dopamine release in psychosis
Mizrahi, R., Addington, J., Rusjan, P. M., Suridjan, I., Ng, A., Boileau, I., Pruessner, J. C., Remington, G., Houle, S., & Wilson, A. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.009 · Cited by 277
Laruelle, M., Wallace, E., Seibyl, J. P., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S. S., Neumeyer, J. L., Charney, D. S., Hoffer, P. B., & Innis, R. B. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.131 · Cited by 268
Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies
Fusar-Poli, P., & Meyer-Lindenberg, A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr180 · Cited by 262
Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A. P., Bhattacharyya, S., Allen, P., McGuire, P. K., & Howes, O. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.017 · Cited by 253
Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia
Hietala, J., Syvälahti, E., Vilkman, H., Vuorio, K., Räkköläinen, V., Bergman, J., Haaparanta, M., Solin, O., Kuoppamäki, M., Eronen, E., et al. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00113-3 · Cited by 243
Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M.-C., Grasby, P. M., & McGuire, P. K. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.77 · Cited by 234
Chuhma, N., Mingote, S., Moore, H., & Rayport, S. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.027 · Cited by 233
Self-citationDeserno, L., Huys, Q. J. M., Boehme, R., Buchert, R., Heinze, H.-J., Grace, A. A., Dolan, R. J., Heinz, A., & Schlagenhauf, F. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417219112 · Cited by 233
Wilson, A. A., McCormick, P., Kapur, S., Willeit, M., Garcia, A., Hussey, D., Houle, S., Seeman, P., & Ginovart, N. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050155n · Cited by 226
McGowan, S., Lawrence, A. D., Sales, T., Quested, D., & Grasby, P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.2.134 · Cited by 226
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors.
Halldin, C., Farde, L., Högberg, T., Mohell, N., Hall, H., Suhara, T., Karlsson, P., Nakashima, Y., & Swahn, C. (1995) · PubMed · Cited by 223
Mukherjee, J., Yang, Z.-Y., Das, M. K., & Brown, T. (1995) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(94)00117-3 · Cited by 219
Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L. S., & Laruelle, M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.007 · Cited by 213 · cited 2×
“Furthermore, excess striatal DA predicts treatment response of psychosis to antipsychotics (58) and is higher in patients who respond to antipsychotics (81).”
Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M.-C., Montgomery, A. J., Grasby, P. M., & McGuire, P. (2011) · Molecular Psychiatry · doi:10.1038/mp.2009.108 · Cited by 207
Slifstein, M., & Laruelle, M. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00214-1 · Cited by 204
Self-citationHowes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., & Turkheimer, F. (2013) · Brain · doi:10.1093/brain/awt264 · Cited by 198 · cited 3×
“The finding of increased Ki cer (91) is potentially susceptible to group differences in cerebellar concentration of [(18)F]DOPA.”
Decreased Dopamine D2 Receptor Binding in the Anterior Cingulate Cortex in Schizophrenia
Suhara, T., Okubo, Y., Yasuno, F., Sudo, Y., Inoue, M., Ichimiya, T., Nakashima, Y., Nakayama, K., Tanada, S., Suzuki, K., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.1.25 · Cited by 194
Haber, S. N., Ryoo, H., Cox, C., & Lu, W. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903620308 · Cited by 188
Speculation on the Meaning of Cerebral Metabolic Hypofrontality in Schizophrenia
Weinberger, D. R., & Berman, K. F. (1988) · Schizophrenia Bulletin · doi:10.1093/schbul/14.2.157 · Cited by 183
Basal ganglia pathology in schizophrenia: dopamine connections and anomalies
Pérez‐Costas, E., Meléndez‐Ferro, M., & Roberts, R. C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06604.x · Cited by 172
PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia
Karlsson, P., Farde, L., Halldin, C., & Sedvall, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.761 · Cited by 172
Stress-Induced Dopamine Release in Humans at Risk of Psychosis: a [11C]Raclopride PET Study
Soliman, A., O’Driscoll, G. A., Pruessner, J. C., Holahan, A.-L. V., Boileau, I., Gagnon, D., & Dagher, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301597 · Cited by 171
Gonzales, K. K., & Smith, Y. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12762 · Cited by 166
Narendran, R., Slifstein, M., Guillin, O., Hwang, Y., Hwang, D.-R., Scher, E., Reeder, S., Rabiner, E., & Laruelle, M. (2006) · Synapse · doi:10.1002/syn.20325 · Cited by 166
Self-citationLaruelle, M. A., Abi‐Dargham, A., van Dyck, C. H., Gil, R. B., D’Souza, D. C., Krystal, J. H., Seibyl, J. P., Baldwin, R. M., & Innis, R. B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00257-7 · Cited by 164
Self-citationPresynaptic dopaminergic function in the striatum of schizophrenic patients
Dao-Castellana, M.-H., Paillère-Martinot, M.-L., Hantraye, P., Attar-Lévy, D., Rémy, P., Crouzel, C., Artiges, E., Féline, A., Syrota, A., & Martinot, J.-L. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00102-8 · Cited by 160
The dopaminergic basis of human behaviors: A review of molecular imaging studies
Egerton, A., Mehta, M. A., Montgomery, A. J., Lappin, J. M., Howes, O. D., Reeves, S. J., Cunningham, V. J., & Grasby, P. M. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.005 · Cited by 159
Kumakura, Y., Cumming, P., Vernaleken, I., Buchholz, H.-G., Siessmeier, T., Heinz, A., Kienast, T., Bartenstein, P., & Gründer, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0805-07.2007 · Cited by 159
Bentivoglio, M., & Morelli, M. (2005) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(05)80005-3 · Cited by 157
Kegeles, L. S., Slifstein, M., Frankle, W. G., Xu, X., Hackett, E., Bae, S., Gonzales, R., Kim, J., Álvarez, B. M., Gil, R. B., et al. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.33 · Cited by 146
Self-citationLaakso, A., Vilkman, H., Alakare, B., Haaparanta‐Solin, M., Bergman, J., Solin, O. H., Peurasaari, J., Räkköläinen, V., Syvälahti, E. K. G., & Hietala, J. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.269 · Cited by 144
Abi‐Dargham, A., Martínez, D., Mawlawi, O. R., Simpson, N. R., Hwang, D., Slifstein, M., Anjilvel, S., Pidcock, J., Guo, N., Lombardo, I., et al. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200002000-00003 · Cited by 143
Self-citationBuchsbaum, M. S., Christian, B. T., Lehrer, D. S., NARAYANAN, T., SHI, B., Mantil, J., Kemether, E. M., Oakes, T. R., & Mukherjee, J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.042 · Cited by 140
Talvik, M., Nordström, A., Olsson, H., Halldin, C., & Farde, L. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003699 · Cited by 136
Kessler, R. M., Woodward, N. D., Riccardi, P., Li, R., Ansari, M. S., Anderson, S., Dawant, B., Zald, D., & Meltzer, H. Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.029 · Cited by 136 · cited 5×
“Of the nine studies in thalamus (16, 84-87, 94-97), only one ((94), which overlaps with (98)) found lower D2 in SZ, and meta-analysis (88) was negative.”
InfluentialAbi‐Dargham, A., Xu, X., Thompson, J. L., Gil, R. B., Kegeles, L. S., Urban, N., Narendran, R., Hwang, D., Laruelle, M. A., & Slifstein, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111409265 · Cited by 135
Self-citationRabiner, E. A., Slifstein, M., Nóbrega, J. N., Plisson, C., Huiban, M., Raymond, R., Diwan, M., Wilson, A. A., McCormick, P. N., Gentile, G., et al. (2009) · Synapse · doi:10.1002/syn.20658 · Cited by 132
Self-citationAllen, P., Luigjes, J., Howes, O. D., Egerton, A., Hirao, K., Valli, I., Kambeitz, J., Fusar-Poli, P., Broome, M., & McGuire, P. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr194 · Cited by 129
Kambeitz, J. P., Abi‐Dargham, A., Kapur, S., & Howes, O. D. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.132308 · Cited by 127
Self-citationDecreased striatal dopamine transporter binding in vivo in chronic schizophrenia
Laakso, A., Bergman, J., Haaparanta‐Solin, M., Vilkman, H., Solin, O. H., Syvälahti, E. K. G., & Hietala, J. A. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00095-5 · Cited by 124
Low Dopamine D2Receptor Binding in Subregions of the Thalamus in Schizophrenia
Yasuno, F., Suhara, T., Okubo, Y., Sudo, Y., Inoue, M., Ichimiya, T., Takano, A., Nakayama, K., Halldin, C., & Farde, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1016 · Cited by 122
6-18F-DOPA PET study in patients with schizophrenia
Elkashef, A. M., Doudet, D. J., Bryant, T., Cohen, R. M., Li, S.-H., & Wyatt, R. J. (2000) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(00)00064-0 · Cited by 118
Cropley, V., Fujita, M., Bara‐Jimenez, W., Brown, A. K., Zhang, X., Sangare, J., Herscovitch, P., Pike, V. W., Hallett, M., Nathan, P. J., et al. (2008) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2007.11.003 · Cited by 117
Graff‐Guerrero, A., Mizrahi, R., Agid, O., Marcon, H., Barsoum, P., Rusjan, P., Wilson, A. A., Zipursky, R. B., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.199 · Cited by 116
Striatal dopamine release in schizophrenia comorbid with substance dependence
Thompson, J. L., Urban, N., Slifstein, M., Xu, X., Kegeles, L. S., Girgis, R. R., Beckerman, Y., Harkavy‐Friedman, J., Gil, R. B., & Abi‐Dargham, A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.109 · Cited by 115
Self-citationStriatal and extrastriatal dopamine release measured with PET and [18F] fallypride
Slifstein, M., Kegeles, L. S., Xu, X., Thompson, J. L., Urban, N., Castrillon, J., Hackett, E., Bae, S. ‐., Laruelle, M., & Abi‐Dargham, A. (2010) · Synapse · doi:10.1002/syn.20734 · Cited by 115
Self-citationCumming, P. D., & GJEDDE, A. H. (1998) · Synapse · Cited by 110
Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., & Nagatsu, T. (1994) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02250926 · Cited by 107
Cropley, V. L., Innis, R. B., Nathan, P. J., Brown, A. K., Sangare, J. L., Lerner, A., Ryu, Y. H., Sprague, K. E., Pike, V. W., & Fujita, M. (2008) · Synapse · doi:10.1002/syn.20506 · Cited by 104
Mueller, H. T., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.004 · Cited by 102
Mizrahi, R., Kenk, M., Suridjan, I., Boileau, I., George, T. P., McKenzie, K., Wilson, A. A., Houle, S., & Rusjan, P. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.347 · Cited by 101
Akil, M., Edgar, C. L., Pierri, J. N., Casali, S., & Lewis, D. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00282-6 · Cited by 101
Enkephalin Disinhibits Mu Opioid Receptor-Rich Striatal Patches via Delta Opioid Receptors
Banghart, M. R., Neufeld, S. Q., Wong, N. C., & Sabatini, B. L. (2015) · Neuron · doi:10.1016/j.neuron.2015.11.010 · Cited by 100
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT
Lavalaye, J., LINSZEN, D. H., Booij, J., Dingemans, P. M. A. J., Reneman, L., Habraken, J. B. A., Gersons, B. P. R., & van Royen, E. A. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00023-2 · Cited by 98
Glenthoj, B. Y., Mackeprang, T., Svarer, C., Rasmussen, H., Pinborg, L. H., Friberg, L., Baaré, W. F. C., Hemmingsen, R., & Videbæk, C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.010 · Cited by 96
Kemel, M. L., Desban, M., Glowinski, J., & Gauchy, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.9006 · Cited by 96
Kegeles, L. S., Slifstein, M., Xu, X., Urban, N., Thompson, J. L., Moadel, T., Harkavy‐Friedman, J., Gil, R. B., Laruelle, M. A., & Abi‐Dargham, A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.027 · Cited by 91
Self-citationZubieta, J., Taylor, S., Huguelet, P., Koeppe, R., Kilbourn, M., & Frey, K. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00981-1 · Cited by 81
Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET
Nozaki, S., Kato, M., Takano, H., Ito, H., Takahashi, H., Arakawa, R., Okumura, M., Fujimura, Y., Matsumoto, R., Ota, M., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.006 · Cited by 81
Talvik, M., Nordström, A., Okubo, Y., Olsson, H., Borg, J., Halldin, C., & Farde, L. (2006) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2006.05.009 · Cited by 80
Dopamine transporter change in drug-naı̈ve schizophrenia: an imaging study with 99mTc-TRODAT-1
Hsiao, M., Lin, K., Liu, C.-Y., Tzen, K., & Yen, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00006-9 · Cited by 77
Visualization of extrastriatal dopamine D2 receptors in the human brain
KESSLER, R. M., Mason, N. S., Votaw, J. R., de Paulis, T., Clanton, J. A., Ansari, M. S., Schmidt, D. E., Manning, R. G., & Bell, R. L. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90825-o · Cited by 77
Effects of Acute Metabolic Stress on Striatal Dopamine Release in Healthy Volunteers
Adler, C. M., Elman, I., Weisenfeld, N., Kestler, L., Pickar, D., & Breier, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00153-0 · Cited by 77
Yang, Y.-K., Yu, L., Yeh, T.-L., Chiu, N.-T., Chen, P., & Lee, H. I. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1496 · Cited by 75
A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover
Sossi, V., Doudet, D. J., & Holden, J. E. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200104000-00015 · Cited by 72
Slifstein, M., Hwang, D., Huang, Y. H., Guo, N., Sudo, Y., Narendran, R., Talbot, P. S., & Laruelle, M. A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1830-x · Cited by 70
Self-citationMateos, J. J., Lomeña, F., Parellada, E., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0570-5 · Cited by 65
Vernaleken, I., Buchholz, H., Kumakura, Y., Siessmeier, T., Stoeter, P., Bartenstein, P., Cumming, P. D., & Gründer, G. (2006) · Human Brain Mapping · doi:10.1002/hbm.20325 · Cited by 64
In Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia
Taylor, S. F., Koeppe, R. A., Tandon, R., Zubieta, J. K., & Frey, K. A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00165-2 · Cited by 62
Riccardi, P., Baldwin, R., Salomon, R. M., Anderson, S., Ansari, M. S., Li, R., Dawant, B. M., Bauernfeind, A. L., Schmidt, D. E., & KESSLER, R. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.022 · Cited by 60
Pogarell, O. M., Koch, W., Karch, S., Dehning, S., Müller, N., Tatsch, K., Poepperl, G., & Möller, H. ‐. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1306313 · Cited by 59
Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia
Kosaka, J., Takahashi, H., Ito, H., Takano, A., Fujimura, Y., Matsumoto, R., Nozaki, S., Yasuno, F., Okubo, Y., Kishimoto, T., et al. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.03.018 · Cited by 59
Substance P Weights Striatal Dopamine Transmission Differently within the Striosome-Matrix Axis
Brimblecombe, K. R., & Cragg, S. J. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0870-15.2015 · Cited by 58
Kumakura, Y., Vernaleken, I., Gründer, G., Bartenstein, P., GJEDDE, A. H., & Cumming, P. D. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600079 · Cited by 58
Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naïve schizophrenic patients
Schmitt, G., la Fougère, C., Dresel, S. H. J., Frodl, T., Hahn, K. M., Möller, H. ‐., & Meisenzahl, E. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.010 · Cited by 49
Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia
Rice, M. W., Roberts, R. C., Meléndez‐Ferro, M., & Pérez‐Costas, E. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0901-y · Cited by 47
Mateos, J. J., Lomeña, F., Parellada, E., Font, M., Fernandez, E., Pavı́a, J., Prats‐Galino, A., Pons, F., & Bernardo, M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2250-2 · Cited by 47
Midbrain dopamine D2/3 receptor binding in schizophrenia
Tuppurainen, H., Kuikka, J. T., Laakso, M. P., Viinamäki, H. T., Husso, M., & Tiihonen, J. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0649-3 · Cited by 41
Suridjan, I., Rusjan, P., Addington, J., Wilson, A. A., Houle, S., & Mizrahi, R. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110181 · Cited by 38
Kish, S. J., Robitaille, Y., El‐Awar, M., Clark, B., Schut, L. J., Ball, M. J., Young, L. T., Currier, R. D., & Shannak, K. S. (1992) · Neurology · doi:10.1212/wnl.42.8.1573 · Cited by 38
Arakawa, R., Ichimiya, T., Ito, H., Takano, A., Okumura, M., Takahashi, H., Takano, H., Yasuno, F., Kato, M., Okubo, Y., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.04.009 · Cited by 37
18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls
Lehrer, D. S., Christian, B. T., Kirbas, C., Chiang, M., Sidhu, S. S., Short, H., Wang, B., Shi, B., Chu, K.-W., Merrill, B., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.043 · Cited by 34
Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia
Yoder, K. K., Hutchins, G. D., Morris, E. D., Brashear, A., Wang, C., & Shekhar, A. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.015 · Cited by 34
Hitri, A., Casanova, M. F., Kleinman, J. E., Weinberger, D. R., & Wyatt, R. J. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00202-e · Cited by 32
Poels, E. M. P., Girgis, R. R., Thompson, J. L., Slifstein, M., & Abi‐Dargham, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3026-8 · Cited by 25
Self-citationSynaptology of Dopamine Neurons
Sesack, S. R. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-56051-4_4 · Cited by 22
Cited by
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 601
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Striatal dopamine mediates hallucination-like perception in mice
Schmack, K., Bosc, M., Ott, T., Sturgill, J. F., & Kepecs, A. (2021) · Science · doi:10.1126/science.abf4740 · Cited by 253
Metadata
- Authors
- Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 81
- Issue
- 1
- Pages
- 31-42
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2325014163
- Cited by
- 297
- References
- 130
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.